Altered SPX expression has been observed in a range of metabolic and systemic conditions, including obesity and metabolic syndrome, type 2 diabetes, hypertension, anxiety and depression, chronic kidney disease, non-alcoholic fatty liver disease, and aging, among others, highlighting its potential as both a diagnostic biomarker and a therapeutic target. This evidence concerns the gene SPX and metabolic dysfunction-associated steatotic liver disease.